CSF2 and melanoma: In 2015, T-VEC (Talimogene laherparepvec; IMLIGYC®), a recombinant human Herpes virus (HSV-1, dsDNA virus) expressing GM-CSF (granulocyte-macrophage colony-stimulating factor) was approved by the US Food and Drug Administration (FDA) for the local treatment of recurrent, unresectable melanoma in adult patients that could not undergo further surgery.